Loading...
•
Mar 31, 2020
Ironwood Pharmaceuticals Q1 2020 Earnings Report
Reported first quarter 2020 results, which included revenue growth and GAAP net income, but withdrew remainder of previously disclosed 2020 financial guidance due to COVID-19 uncertainties.
Key Takeaways
Ironwood Pharmaceuticals reported a 16% year-over-year increase in total revenue to $80 million for the first quarter of 2020, driven primarily by U.S. LINZESS collaboration revenue of $71 million. The company delivered GAAP net income of $3 million and adjusted EBITDA of $14 million. However, due to COVID-19 uncertainties, Ironwood withdrew the remainder of its previously disclosed 2020 financial guidance, while maintaining its adjusted EBITDA guidance of >$105 million.
LINZESS total prescription demand grew by 11% year-over-year.
Total revenue increased by 16% year-over-year to $80 million, driven by U.S. LINZESS collaboration revenue of $71 million.
GAAP net income was $3 million and adjusted EBITDA was $14 million.
Maintained 2020 adjusted EBITDA guidance of >$105 million but withdrew the remainder of previously disclosed 2020 financial guidance due to COVID-19 uncertainties.
Revenue by Segment
Forward Guidance
Ironwood maintains its 2020 adjusted EBITDA guidance of >$105 million but withdraws the remainder of previously disclosed 2020 financial guidance due to COVID-19 uncertainties.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...